Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
06/2005
06/14/2005US6906034 Insulin like growth factor binding protein complex for use as wound healing agent in animals and humans
06/14/2005US6906033 Isolated DNA encoding amino acid sequences, serine protease inhibitor, host cell transformed with a DNA molecule, Kunitz type Inhibitor, blood coagulation factors
06/14/2005US6906032 Cyclic peptidomimetic urokinase receptor antagonists
06/14/2005US6906031 Polyacid glycopeptide derivatives
06/14/2005US6906029 Insulin-like growth factor binding protein (IGFBP-5)
06/14/2005US6906028 Stable insulin formulations
06/14/2005US6906027 Composition for nasal administration of insulin
06/14/2005US6906026 Methods for treating conditions associated with the accumulation of excess extracellular matrix
06/14/2005US6905873 Recombinant p53 adenovirus methods and compositions
06/14/2005US6905856 Soluble GlcNAc phosphotransferase
06/14/2005US6905855 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
06/14/2005US6905846 Nucleic acids encoding factor X deletion mutants and analogues thereof
06/14/2005US6905845 Isolated nucleic acids; allergies sensitivity
06/14/2005US6905842 Modulation signal transduction; isolated nucleic acids; genetic engineering
06/14/2005US6905832 Uses of peptides derived from the cytoplasmic domain of the amyloid protein precursor (APP)
06/14/2005US6905820 Polyamide nucleic acid derivatives, and agents and processes for preparing them
06/14/2005US6905714 Method for modulating steroidogenic activity
06/14/2005US6905704 Animal extracts; hypotensive agent; storage stability
06/14/2005US6905690 Seaweed extract (from red macroalgae); storage stability
06/14/2005US6905688 Comprises therapeutic fusion proteins for diagnosis and treatment of cancers, neovascularization and autoimmune diseases
06/14/2005US6905687 Fusion proteins; immunogens; solid phase synthesis; kits
06/14/2005US6905686 Active immunization for treatment of alzheimer's disease
06/14/2005US6905685 Antiproliferative agents; monoclonal antibodies; blocking immunology response; autoimmune disease, antidiabetic agents, antiarthritic agents, antitumor, anticancer agents
06/14/2005US6905684 Preventives and remedies for diffuse lung diseases
06/14/2005US6905683 Prevents side effects such as systemic activation of coagulation system, bleeding
06/14/2005US6905682 Hybrid nucleic acids, ant antibodies thereof; insecticide
06/14/2005US6905681 Methods for selectively stimulating proliferation of T cells
06/14/2005US6905680 Induction of lymphocytes; obtain cells, activate cells, incubate with activator, monitor lymphocyte proliferation
06/14/2005US6905677 Synergistic mixture of nucleoside and interferons
06/14/2005US6905676 Cytokines; anttumor agents; viricides; bactericides; antiinflammatory agents
06/14/2005CA2459239C Hydrogenated castor oil dispersed in a lipid for pharmaceutically elegant topical ointment
06/14/2005CA2400318C Botulinum toxin pharmaceutical compositions
06/14/2005CA2285463C A combination therapy for hiv infections
06/14/2005CA2284100C New gene with upregulated expression in metastatic human tumor cells and a protein coded thereby, methods of production, and use thereof
06/14/2005CA2246708C Vaccine for b-cell malignancies
06/14/2005CA2164088C Plasmids suitable for gene therapy
06/14/2005CA2100423C Parathyroid hormone analogs having parathyroid hormone-like activity
06/14/2005CA2098842C Use of host cell phospholipids for inhibiting microbial colonization
06/11/2005CA2450540A1 Antimicrobial peptides with reduced hemolysis and methods of their use
06/09/2005WO2005052596A1 A reference solution
06/09/2005WO2005052166A1 Recombinant peptide vector comprising the gene for treatment for autoimmune diseases.
06/09/2005WO2005052165A1 Chimeric type 5/type 11 or type 35 adenovirus vector for preventing infection with antihuman immunodeficiency virus
06/09/2005WO2005052157A1 Il-23 and its receptor; related reagents and methods
06/09/2005WO2005052139A2 Method of inducing memory b cell development and terminal differentiation
06/09/2005WO2005052007A1 Recombinant anti-cd64-immunotoxins
06/09/2005WO2005052001A2 Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
06/09/2005WO2005052000A2 Anti-il-20 antibodies and binding partners and methods of using in inflammation
06/09/2005WO2005051996A2 Protein from horn fly saliva that disrupts hemostasis
06/09/2005WO2005051994A2 Ztnf11, a tumor necrosis factor
06/09/2005WO2005051993A1 Novel muscle growth regulator
06/09/2005WO2005051990A2 Polynucleotides overexpressed in breast cancer cells, compositions and methods for the therapy and diagnosis of breast cancer
06/09/2005WO2005051988A2 Compositions and methods for the treatment of systemic lupus erythematosis
06/09/2005WO2005051986A1 Polyvalent allergy vaccine
06/09/2005WO2005051981A1 Biologically active peptides comprising isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonine (ivtntt)
06/09/2005WO2005051980A1 Depeptidized inhibitors of hepatitis c virus ns3 protease
06/09/2005WO2005051975A2 Methods for obtaining molecules with reduced immunogenicity
06/09/2005WO2005051971A1 Reduction of dermal scarring
06/09/2005WO2005051871A2 Implantable sensors and implantable pumps and anti-scarring agents
06/09/2005WO2005051799A2 Peptide increasing fusiogenic capacity of a gamete
06/09/2005WO2005051483A2 Electrical devices and anti-scarring agents
06/09/2005WO2005051451A2 Electrical devices and anti-scarring agents
06/09/2005WO2005051444A2 Soft tissue implants and anti-scarring agents
06/09/2005WO2005051433A1 Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent
06/09/2005WO2005051432A1 Therapeutic regimen for treating cancer
06/09/2005WO2005051421A2 Use of shigella invaplex to transport functional proteins and transcriptionally active nucleic acids across mammalian cell membranes in vitro and in vivo
06/09/2005WO2005051418A2 Pharmaceutical formulations for the sustained release of interleukins and therapeutic applications thereof
06/09/2005WO2005051417A1 Pharmaceutical formulations for the sustained release of interferons and therapeutic applications thereof
06/09/2005WO2005051416A1 Pharmaceutical formulations for the sustained release of one or more active principles and applications thereof, such as therapeutic applications
06/09/2005WO2005051415A1 Method for preventing and treating diabetes using neurturin
06/09/2005WO2005051414A1 Use of c4bp core region as a cd40 agonist
06/09/2005WO2005051413A2 Disease associated genes
06/09/2005WO2005051412A2 Regulation of sperm function
06/09/2005WO2005051411A1 Novel drug: oxachelin and its derivatives
06/09/2005WO2005051410A1 Hepatitis c virus inhibitors
06/09/2005WO2005051409A1 Plant extracts for the treatment of increased bone resorption
06/09/2005WO2005051408A1 Method for preventing and treating diabetes using dg119
06/09/2005WO2005051367A1 Carboxamide and amino derivatives and methods of their use
06/09/2005WO2005051359A1 Macromolecular drug complexes having improved stability and therapeutic use of the same
06/09/2005WO2005051331A2 Chaperone-based therapy for niemann-pick disease
06/09/2005WO2005051328A2 Amelioration of macular degeneration and other ophthalmic diseases
06/09/2005WO2005051327A2 Glycopegylated erythropoietin
06/09/2005WO2005051321A2 Treatment of inflammatory bowel disease through induction of indoleamine 2,3-dioxygenase
06/09/2005WO2005051291A2 B-cell-targeted toxin for immuno response reduction
06/09/2005WO2005051289A2 Homogeneous preparations of chimeric proteins
06/09/2005WO2005051232A2 Soft tissue implants and anti-scarring agents
06/09/2005WO2005040142A9 Novel keto-oxadiazole derivatives as cathepsin inhibitors
06/09/2005WO2005035773A8 Modified cea /b7 vector
06/09/2005WO2005032581A3 Hybrid molecules having factor vii/viia activity
06/09/2005WO2005030787A3 Oligonucleotide compositions and methods for treating disease including inflammatory conditions
06/09/2005WO2005030136A3 Tumor vaccine
06/09/2005WO2005028616A9 Morphogen compositions and methods of use thereof to treat heart disorders
06/09/2005WO2005028499A3 Peptide that binds to a broadly neutralizing anti-hiv antibody-structure of 4e10 fab fragment complex, uses thereof, compositions therefrom
06/09/2005WO2005026194A3 Granulysin peptides and methods of use thereof
06/09/2005WO2005025604A3 Use of hmgb and hmgb fragments to decrease specific immune response
06/09/2005WO2005021592A3 Enhancing the circulating half-life of interleukin-2 proteins
06/09/2005WO2005014812A3 An antisense oligonucleotide to inhibit melanoma inhibitory activity, mia
06/09/2005WO2005014039A3 Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative diseases
06/09/2005WO2005014021A3 Use of zkw peptide for preparing an inhibitor drug against platelet aggregation
06/09/2005WO2005011722A3 Use of vegf-c or vegf-d in reconstructive surgery
06/09/2005WO2005008248A3 Diagnosis and treatment of cervical cancer
1 ... 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 ... 3163